Soligenix, Inc. (SNGX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.4898 |
| Open | 0.5000 |
| Bid | 0.5300 x 800 |
| Ask | 0.6000 x 3100 |
| Day's Range | 0.5601 - 0.6000 |
| 52 Week Range | 0.3800 - 1.3400 |
| Volume | |
| Avg. Volume | 141,450 |
| Market Cap | 25.681M |
| Beta (5Y Monthly) | 1.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3630 |
| Earnings Date | Mar 28, 2022 - Apr 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine Platform
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the patent application titled "Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines." The allowed claims are directed to unique, proprietary compositions and me
- Zacks Small Cap Research
SNGX: Phase 2a Trial of SGX302 in Psoriasis to Initiate in Second Half of 2022…
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update SGX302 for Psoriasis Soligenix, Inc. (NASDAQ:SNGX) will be developing synthetic hypericin (the active ingredient in HyBryte) as part of a photodynamic therapy in mild-to-moderate psoriasis patients under the research name SGX302. Psoriasis is a common, chronic, noncontagious, multisystem inflammatory condition that
- PR Newswire
Soligenix to Present at the H.C. Wainwright Global Investment Conference
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming H.C. Wainwright Global Investment Conference. The conference will be held May 23 through 26, 2022 with presentations, one-on-one meetings, and networking. The on-demand presentation will be available Tue
